Replies to post #6030 on Marker Therapeutics Inc (MRKR)

[TOB]

You're welcome. Thanks for clearing that up, I was wondering if I was missing something. ;-)

Thanks for that post TOB.
It was the last 8k I was referring to. Just reread it now and I must apologize that there is no mention of restriction the shares. They speak of registering them.
The sale of those shares should not be a concern since he is over 10% and per your explanation he should be long. -tipizzazz24

OT, what is your opinion of them uplisting to a more prestigious exchange. Rk posted what is needed to qualify for uplisting to Nasdaq. Do you have any experience with any of your holdings doing this and what is the normal time frame? TIA, peace! -tipizzazz24

Well... on topic for TPIV IMO, just a different subject.

I don't want to press this issue too much, as though it's imminent for example, as I don't know what the company has said on the subject. If they haven't discussed it publicly they may just announce it as a done deal. They may also be qualified, but decide the timing is not right. I've no idea.

I did write a fairly detailed post on up-listing to the NASDAQ, that shows it is quite within reach without needing a reverse split. With that said, with a rising share price and good clinical trial results, however they get there is good.

Obviously one big advantage to up-listing is many institutions can only buy stocks that are exchange listed, and often not below $5. Yet, TPIV already has strong institutional ownership, with that increasing as more warrants are exercised. Massive really if you consider just Dart is held just below 50% ownership.

So with such a low public float, where will those institutions find the shares they need? Also some are mandated to buy if and when TPIV is on the Russell for example.

The answer is they have to pay up for them, forward splits, all sorts of good things.

That doesn't mean shares won't be added to the O/S, but... the share structure looks very good now. Again, always assuming good clinical trial results.

Here below is the post in which I detailed the up-listing subject. The key take-away, qualification for the NASDAQ-Capital Market can start with a $2 closing price with the other criteria met.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114786037

[itsthebox1]

The restricted shares were mentioned in the pr